Compare Kyndryl Holdings Inc (KD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Recursion Pharmaceuticals Inc — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Kyndryl Holdings Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KD | RXRX | |
|---|---|---|
Market Cap | $2.59B | $2.14B |
Volume | 5,354,348 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $28.92 | $6.79 |
52-Week Low | $10.59 | $2.84 |
Typical Hold Time | 36 Days | 23 Days |
Enterprise Value | $5.41B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $11.88, up 3.76% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q4 2025 and Q1 2026 expectations. Fundamentals show improving profitability with 2025 net income of $252M (1.67% margin) and strong cash flow generation of $236M. Recent news highlights AI-focused initiatives including new innovation labs and strategic acquisitions.
Outlook remains cautious with analyst consensus at Hold (71.42%) and $14.67 price target offering 23% upside. Key risks include inconsistent earnings performance, competitive pressures in IT services, and high debt levels at 30.67% debt-to-asset ratio. The stock presents potential for recovery if AI investments translate to sustained revenue growth and margin expansion.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
